Photodynamic Therapy for the Prevention of Lung Cancer

Lung Cancer Clinical Trial

— PEARL  

Official title:

Photodynamic Therapy for the Prevention of Lung Cancer (PEARL)

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03346304
• Other study ID #: UCL/13/0390
• Status: Withdrawn
• Phase: Phase 2/Phase 3
• Start date: September 2018
• Est. completion date: October 2024

Study information

• Verified date: January 2019
• Source: University College, London
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

PEARL is a phase III multicentre 2:1 randomised controlled trial, with an incorporated phase II (pilot) component. All patients consented/registered onto the trial will have an autofluorescence bronchoscopy (AFB) to check for the presence of high grade lesions (HGLs) in the lung, as verified by tissue biopsy. Only patients with one or more histologically confirmed lung HGL will be randomised to receive either photodynamic therapy (PDT) treatment with surveillance (=intervention), or surveillance alone (=control).

The overall aim of the phase II pilot is to demonstrate a >20% response in the PDT group (at least 3 out of 21 PDT patients), compared to a minimum response of 5%. This will be used as an efficacy signal to determine whether the trial will continue into phase III. Response will be measured by regression of high grade lesions (HGLs) to either low grade lesions (LGLs), or to normal epithelium at 6 months post treatment (blind assessment). The overall aim of the phase III is to show that the time period over which HGLs progress to invasive lung cancer is significantly longer when treated with PDT compared to surveillance alone.

Description:

Background: Squamous cell carcinoma of the lung develops through a transition of progressive cytological aberration, from normal to metaplasia, mild, moderate, and severe dysplasia and then carcinoma in situ (CIS) before becoming an invasive cancer. Progression rates to invasive carcinoma can vary depending on the initial grade of lesion and it is generally accepted that high-grade lesions are more likely to progress to invasive cancer than low-grade lesions. Early detection and treatment of these lesions is critical to improving survival. There is no evidence base examining how, or whether these high-grade lesions (HGLs) should be treated, resulting in diverse treatment practices both nationally and internationally. This is the first randomised clinical trial of a bronchoscopic intervention in treating HGLs using PDT.

Treatment: Treatment-arm patients will receive two courses of PDT treatment using the photosensitiser drug Fotolon®. Fotolon®, which preferentially accumulates in HGLs, is first administered via IV infusion. Patients then undergo bronchoscopy during which their HGLs are irradiated with red light (via non-heat emitting laser). Red-light activation of the photosensitiser causes chemical transformation of the cells and cell death.

Follow Up: Follow up in both arms consists of AFB surveillance at 6 and 12 months, then every 6-12 months (depending on the appearance of lesions), with annual CT scanning of the thorax, and annual spirometry. Biological samples for translational analysis will be taken at baseline and each subsequent trial visit.

Duration of recruitment: Anticipated recruitment for phase II is 1 year (12 months), and an additional 2 years (24 months) for the phase III.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: October 2024
• Est. primary completion date: September 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients with =1 histologically confirmed lung HGL (defined as severe dysplasia or carcinoma in situ) PRE-REGISTRATION: High likelihood of presence of lung HGLs as evaluated by investigator (e.g. because patient part of existing surveillance cohort or referred to trial site) and inclusion/exclusion criteria below. PRE-RANDOMISATION: Following registration and AFB, only patients with =1 lung HGLs confirmed histologically can be continue to randomisation provided they continue to meet inclusion/exclusion criteria below.

2. Absence of metastatic disease or other primary cancers as confirmed by CT thorax within 28 days prior to registration only)

3. Male or female patients =18 years of age

4. No upper age limit but life expectancy must be at least 3 years

5. ECOG Performance Score 0-2

6. FEV1 = 25% of predicted

7. DLCO/TLCO = 20% of predicted (within 28 days prior to registration only)

8. Women of child-bearing potential (WOCBP), or men with female partners who are pregnant or WOCBP must be willing to practise highly effective methods of birth control starting as soon as possible from the time of informed consent and registration until randomisation (if randomised to the control arm), or until 3 months after the end of their last PDT treatment (if randomised to the intervention arm) . Male patients must also advise their female partners who are WOCBP regarding contraceptive requirements as listed for female patients who are WOCBP.

9. Patients who are WOCBP must also have a negative pregnancy test at the following time points:

• within 14 days prior to registration

• within 21 days prior to randomisation

• and within 24 hours prior to 1st and 2nd PDT treatment, for each lung treated (only if randomised to PDT arm)

10. Ability to give informed consent including the donation of biological samples for translational research

Exclusion criteria:

1. PRE-RANDOMISATION: Finding of (micro)-invasive disease on histology

2. HGLs present for =5 years which have remained stable on autofluorescence bronchoscopy (AFB) surveillance

3. Detection of active cancer or on systemic treatment for cancer, excluding basal cell skin cancers (unless adjacent to the illumination site)

4. Previous radiotherapy to the central airways

5. ECOG Performance Score >2

6. Patients who are anticoagulated for prosthetic heart valves

7. Decompensated heart disease with life expectancy less than 3 years

8. Severe liver and renal insufficiency with life expectancy less than 3 years

9. Porphyria or hypersensitivity against porphyrins or photosensitivity

10. Hypersensitivity to chlorine-e6-trisodium salt or therapy with another photosensitising agent or relevant antibiotics (macrolides) in the last 4 weeks

11. Ophthalmic disease likely to require slit-lamp examination within 60 days of registration/randomisation

12. Planned surgical procedure within 60 days of registration/randomisation

13. Patient unlikely to cooperate with a 3-year follow-up; medical or psychological condition at the discretion of the investigator which would not permit compliance with the protocol or meaningful signed informed consent

14. Participation in another study with an investigational medicinal product within one month prior to registration/randomisation

15. Pregnant or breast feeding women (confirmed by serum/urine ß-HCG)

16. Any other condition which is assessed as an intolerable risk by the investigator upon inclusion in the study

Related Conditions & MeSH terms

• Lung Cancer
• Lung Neoplasms
• Squamous Cell Lung Cancer

Intervention

Other:
• Photodynamic Therapy (PDT)
Photodynamic Therapy (PDT) using photosensitiser drug Fotolon

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
University College, London

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time to site-specific progression	of high grade lesions in the lung to invasive lung cancer; compared between the PDT and control groups	within a 3-year follow-up (incorporates patients from phase II)
Secondary	Site-specific response	(regression, stable appearance, progession or recurrence) of HGLs present at baseline (index lesions); compared between the PDT and control groups	within a 3-year follow-up (incorporates patients from phase II)
Secondary	Number of new HGLs	HGLs identified post-baseline at new sites within the lung (i.e. not at the site of the index lesions); compared between the PDT and control groups	within a 3-year follow-up (incorporates patients from phase II)
Secondary	Number of metachronous endobronchial lung cancers	that develop at remote sites within the lung in both arms	within a 3-year follow-up (incorporates patients from phase II)
Secondary	Cumulative risk of developing lung cancer	as detected on bronchoscopy and CT thorax in patients harbouring HGLs from date of randomisation; compared between the PDT and control groups	within a 3-year follow-up (incorporates patients from phase II)
Secondary	Overall and cancer specific survival	from date of randomisation; compared between the PDT and control groups	within a 3-year follow-up (incorporates patients from phase II)
Secondary	Difference in spirometry (FEV1, FVC) values	to determine whether PDT affects spirometry	at specific time points (6,12,24 and 36 months post randomisation);
Secondary	Adverse events	Based on the maximum toxicity grade for each patient for each event type; compared between the PDT and control groups	within a 3-year follow-up (incorporates patients from phase II)
Secondary	EQ-5D-5L	Health-Related Quality of Life (HRQoL)	at specific time points (6,12,24 and 36 months, and possibly 18 and 30 months, post randomisation); compared between the PDT and control groups
Secondary	EORTC QLQ-LC13	Health-Related Quality of Life (HRQoL)	at specific time points (6,12,24 and 36 months, and possibly 18 and 30 months, post randomisation); compared between the PDT and control groups
Secondary	ACE-27	Health-Related Quality of Life (HRQoL)	at specific time points (6,12,24 and 36 months, and possibly 18 and 30 months, post randomisation); compared between the PDT and control groups